CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

作者： Audrey E. Van Heest1, Feiyang Deng1, Renee T. Zhao2, Nour Saida Harzallah2,3, Heather E. Fleming3,4, Sangeeta N. Bhatia2,3,4,5,6,7,8, Liangliang Hao1,2,3 1Department of Biomedical Engineering,Boston University, 2Institute for Medical Engineering and Science,Massachusetts Institute of Technology, 3Koch Institute for Integrative Cancer Research,Massachusetts Institute of Technology, 4Howard Hughes Medical Institute, 5Broad Institute of Massachusetts Institute of Technology and Harvard, 6Department of Electrical Engineering and Computer Science,Massachusetts Institute of Technology, 7Department of Electrical Engineering and Computer Science,Massachusetts Institute of Technology, 8Department of Medicine,Brigham and Women’s Hospital and Harvard Medical School

简介：

Overview

This protocol describes a CRISPR-Cas-mediated, multianalyte synthetic urine biomarker test that enables point-of-care cancer diagnostics through the ex vivo analysis of tumor-associated protease activities. The Heart Lab is engineering molecular and cellular tools to precisely track and control disease biology.

Key Study Components

Area of Science

• Neuroscience
• Biotechnology
• Diagnostics

Background

• Biofluids are convenient for disease detection but often limited by low quantities of relevant analytes.
• Strategies are being developed to amplify disease-associated signals to improve diagnostic test sensitivity.
• Current methods rely on synthetic biomarkers rather than endogenous disease biomarkers.
• Injected nanosensors release synthetic biomarkers to report disease activity.

Purpose of Study

• To develop a synthetic urine biomarker test for cancer diagnostics.
• To enhance the sensitivity of disease detection through engineered molecular tools.
• To utilize stabilized DNA barcodes for detecting multiple disease signals simultaneously.

Methods Used

• CRISPR-Cas technology for biomarker testing.
• Ex vivo analysis of tumor-associated protease activities.
• Design of responsive detection tools based on disease microenvironments.
• Use of chemically stabilized DNA barcodes for signal detection.

Main Results

• Successful development of a multianalyte synthetic urine biomarker test.
• Improved sensitivity in detecting disease-associated signals.
• Demonstration of the effectiveness of synthetic biomarkers in reporting disease activity.
• Potential for point-of-care diagnostics in cancer detection.

Conclusions

• The synthetic urine biomarker test represents a significant advancement in cancer diagnostics.
• Engineered molecular tools can enhance disease tracking and treatment.
• This approach may lead to more effective point-of-care diagnostic solutions.

Frequently Asked Questions